As Featured In
New Episodes
View all
What is an FDA warning letter, and how should your company respond once it has received one? In today's episode, Darshan Kulkarni talks...
There is growing pressure being placed on pharmaceutical companies to make their clinical trials more transparent. Despite this pressure...
Figuring out how to conduct a coverage analysis can be difficult. Is it necessary for your company? Join Darshan Kulkarni as he talks with...
Virtual reality has been rapidly developing in recent years. What does this mean for bioethics? Join Darshan Kulkarni as he talks about...
What is the FDA’s stance on cannabis, and how has it evolved? Join Darshan Kulkarni as he discusses recent FDA guidance on cannabis, and...